£15 billion and counting… Can Britain afford its medicine?

6 June 2016

Patient engagement is the key to unlocking the pressing issue of how the UK can afford its increasing expenditure on medicines, according to speakers at a public event to be held by the British Pharmacological Society on June 9, during The Times Cheltenham Science Festival. Titled “Can we afford our medicine?” the event will call for research to understand UK patients’ preferences:

Which areas of medicine should be prioritized nationally?
At what level or in what circumstances do improvements in life expectancy or quality of life represent value for money?
How would society benefit from improved use of anonymized patient medical records?

Chaired by well-known broadcaster Vivienne Parry, an expert panel made up of the British Pharmacological Society’s president Professor David Webb, clinical pharmacologist Prof Ken Paterson and clinical trial expert Dr Frances MacDonald will discuss imaginative new approaches to developing and funding new medicines and ask for a second opinion from members of the public.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK